InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.15
(
-0.16%
)
Bitcoin
66,612.29
(
0.63%
)

Replies to post #50 on Cellectis S.A (CLLS)

Replies to #50 on Cellectis S.A (CLLS)

Avispa

09/05/17 7:51 AM

#51 RE: north40000 #50

https://seekingalpha.com/news/3293436-cellectis-29-percent-premarket-fda-hold-studies-ucart123-fatality

n4807g

09/05/17 8:54 AM

#52 RE: north40000 #50

Not uncommon with new therapies. Much too early to draw any conclusions about UCART123. The trial will most likely resume with recommended adjustments.